http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
인간 난소에서 생리 주기에 따른 Mullerian Inhibiting Substance와 그 수용체의 발현
김장흡 ( Jang Heub Kim ),정서호 ( Seo Ho Chung ),최은주 ( Eun Joo Choi ),황성진 ( Hwang Seong Jin ),조현희 ( Hyun Hee Jo ),김미란 ( Mee Ran Kim ),김은중 ( Eun Jung Kim ),김진홍 ( Jin Hong Kim ),류기성 ( Ki Sung Ryu ) 대한산부인과학회 2004 Obstetrics & Gynecology Science Vol.47 No.9
In this study, in order to further understanding of function of Mullerian inhibiting substance (MIS) and the ontogeny of the production profile of biologically active MIS and MIS type II receptor (MISR II), the patterns of their localization according to
( Jang Heub Kim ),( David T Maclaughlin ),( Patricia K Donahoe ) 대한산부인과학회 2014 Obstetrics & Gynecology Science Vol.57 No.5
Mullerian inhibiting substance (MIS), also called anti-Mullerian hormone (AMH), is a member of the transforming growth factor-β super-family of growth and differentiation response modifiers. It is produced in immature Sertoli cells in male embryos and binds to MIS/AMH receptors in primordial Mullerian ducts to cause regression of female reproductive structures that are the precursors to the fallopian tubes, the surface epithelium of the ovaries, the uterus, the cervix, and the upper third of the vagina. Because most gynecologic tumors originate from Mullerian ductderived tissues, and since MIS/AMH causes regression of the Mullerian duct in male embryos, it is expected to inhibit the growth of gynecologic tumors. Purified recombinant human MIS/AMH causes growth inhibition of epithelial ovarian cancer cells and cell lines in vitro and in vitro via MIS receptor-mediated mechanism. Furthermore, several lines of evidence suggest that MIS/AMH inhibits proliferation in tissues and cell lines of other MIS/AMH receptor-expressing gynecologic tumors such as cervical, endometrial, breast, and in endometriosis as well. These findings indicate that bioactive MIS/AMH recombinant protein should be tested in patients against tumors expressing the MIS/AMH receptor complex, perhaps beginning with ovarian cancer because it has the worst prognosis. The molecular tools to identify MIS/AMH receptor expressing ovarian and other cancers are in place, thus, it is possible to select patients for treatment. An MIS/AMH ELISA exists to follow administered doses of MIS/AMH, as well. Clinical trials await the production of sufficient supplies of qualified recombinant human MIS/AMH for this purpose.
Comparative Evaluation of Hysterosalpingography and Laparoscopy in Diagnosis of Infertile Women
Kim, Jang Heub,Kim, Seung Jo CATHOLIC MEDICAL CENTER 1980 Bulletin of the Clinical Research Institute Vol.8 No.1
From 1974 to 1979, inclusively, 91 patients from the Infertility Clinic of St. Mary's Hospital, Catholic Medical College, were evaluated with both HSG and laparoscopy. In 46.6% of the cases there were complete aggrement between HSG and laparoscopy. HSG showed 9.1% false posive and 8% false negative findings. The results showed that premedication with Buscopan Compositum^� in HSG was of benefit in decreasing the incidence of false positive tubal occlusion. Peritubal adhesion was the pathologic process most commonly missed by HSG and diagnosed subsequently by laparoscopy. As for the factors other than tubal occlusion and/or peritubal adhesion, other pelvic diseases were the most common abnormalities discovered by laparoscopy, whereas all intrauterine factors were easily detectable by HSG.
Kim, Jang Heub,Kim, Eun Jung,Kim, Jin Hong,Lee, Jin Woo,Lee, Hun Young CATHOLIC MEDICAL CENTER 1992 Bulletin of the Clinical Research Institute Vol.20 No.1
Forty-four polycystic ovary patients were treated for a total of 57 cycles with intermediate dose FSH. Patient selection was based on hyperandrogenism, oligoovulation, and physical signs. Patients with multiple factor infertility were excluded from the study. Seventeen conception cycles occurred in 17 patients (Pregnancy cycles). The spontaneous abortion rate was 29.4%. Forty cycles did not result in conception (Nonpregnancy cycles, 23 patients). Sixteen pregnancies (94%) occurred within the first 2 treatment cycles. Pregnancy and Nonpregnancy cycles were compared for characteristics associated with a successful outcome. There was no difference in the average cycle lengths, number of baseline follicles, serum estradiol, or number of large follicles on day of hCG. Compared with the Nonpregnancy cycles, the cycles resulting in pregnancy required a significantly higher number of FSH ampules according to body weight. The duration of FSH administration also increased with increasing body weight in the Pregnancy cycles. In the Pregnancy cycles, body weight (X) was correlated to the number of ampules FSH (Y) used (r=0.728) and the following formula was identified: Y=0.33622X-9.3635. Using this formula, the number of treatment days (Z) could be predicted from the number of ampules (Y): Z=(Y-12)÷3+9. Serum testosterone was greater (91.8±41.6 vs 57.1±30.4 ng/ml, p<0.03) and the average BSA was significantly higher in patients who conceived (1.88±0.2 vs. 1.73±0.2 ㎡, p<0.04). Serum LH/FSH ratio on day 5 was higher in the Pregnancy cycles, but not significantly different. Ovarian hyperstimulation occurred in 1 cycle (6%) in the Pregnancy cycles and 14 (35%) in Nonpregnancy cycles. These data suggest 1) the intermediate dose pure FSH protocol is most likely to be successful among more “classic” PCOD patients as evidenced by obesity, high BSA, elevated LH/FSH ratio, and higher testosterone, 2) if pregnancy is to occur, it is most likely to occur within two treatment cycles, 3) patients who do not conceive with intermediate dose FSH are more likely to experience ovarian hyperstimulation, and 4) formulas are provided which help anticipate the number of FSH ampules which will be used and the number of treatment days FSH will be required.
폐경이행기 여성에서 Inhibin A와 Inhibin B의 혈중농도와 난소에서의 발현변화
김장흡 ( Kim Jang Heub ),김미란 ( Kim Mi Lan ),이윤진 ( Lee Yun Jin ),황성진 ( Hwang Seong Jin ),조현희 ( Jo Hyeon Hui ),류기성 ( Lyu Gi Seong ),유영옥 ( Yu Yeong Og ),한구택 ( Han Gu Taeg ),나종구 ( Na Jong Gu ),김진홍 ( Kim Jin 대한산부인과학회 2003 Obstetrics & Gynecology Science Vol.46 No.12
Objective : To understand the physiologic effects and secretion pattern of inhibin A and inhibin B during menstrual cycle and menopausal transition, inhibin A and inhibin B levels were measured. And to detect any changes in expression of inhibins in human
월경주기에 따른 Inhibin A와 B의 혈중 농도 변화
김장흡 ( Jang Heub Kim ),이윤진 ( Yoon Jin Lee ),황성진 ( Seong Jin Hwang ),조현희 ( Hyun Hee Jo ),권동진 ( Dong Jin Kwon ),김은중 ( Eun Jung Kim ),김진홍 ( Jin Hong Kim ),이진우 ( Jin Woo Lee ) 대한산부인과학회 2003 Obstetrics & Gynecology Science Vol.46 No.6
Objective : To understand the physiologic effects and secretion pattern of inhibin A and inhibin B throughout menstrual cycle in the normal reproductive women, serum values of inhibin A and inhibin B were measured. Methods : Inhibin A and inhibin B levels